·The Hindu·15 marks·250–350 words

Assess the relevance of the WHO's 2021 framework on human genome editing for national regulators in developing countries.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Relevance: why it helps developing-country regulators
  2. Limitations

In July 2021, WHO released Human genome editing: a framework for governance. It sets out values, tools and seven illustrative scenarios, and it can be adapted for use at the institutional, national or regional level [1]. The framework matters more after the 2026 death of a six-year-old girl in a Chinese gene-therapy trial, which was left out of a published paper [3]. For developing countries, it is a strong template, but it cannot replace domestic capacity.

Relevance: why it helps developing-country regulators

  • Ready-made blueprint: Countries without a dedicated law can adapt the framework's values and scenarios instead of drafting rules from scratch [1].
  • Registry: The companion recommendations call for a human genome editing registry [2]. The Chinese death was exposed by Science and Retraction Watch, not by any regulator [3]. A registry gives an independent record against which published papers can be checked.
  • Reporting unsafe research: WHO recommends ways for researchers to report concerns [2][6]. Staff inside hospitals would then not have to rely on journalists.
  • Medical travel: The recommendations cover international research and medical travel [2]. Weakly regulated countries can otherwise become destinations for unproven "therapy tourism."
  • Equity: The recommendations also cover IP, education and public engagement [2]. These bear on affordable access, an issue for countries with large rare-disease and sickle-cell burdens.
  • Timely for India: India's first home-grown CRISPR therapy for sickle cell disease, BIRSA-101, was developed by CSIR-IGIB and is moving towards patients [4]. DBT's genome-editing framework is still a 2020 draft [5].

Limitations

  • Soft law: The framework is non-binding, so enforcement depends entirely on national will.
  • Capacity gaps: Many regulators lack specialist reviewers. In India, oversight is split across several bodies. RCGM and institutional biosafety committees check lab-stage work, and CDSCO approves trials under the NDCT Rules, 2019 [4]. Safety data can be lost when work passes from one body to the next.
  • Prevention vs punishment: China's sanctions included dismissal and a five-year debarment, but they came only after outsiders exposed the case [3]. The framework guides governance; it does not provide pre-trial checks on its own.

Overall, the WHO framework is highly relevant as a norm-setting and adaptable scaffold, but its value depends on national implementation. Developing countries should turn it into binding rules, build specialist review cadres and join the global registry. That would make innovation safe and fair, in line with SDG 3 and the right to health under Article 21.

Sources

  1. 1WHO, *Human genome editing: a framework for governance* (2021)adaptable at multiple levels; seven scenarios
  2. 2WHO news release, 12 July 2021: new recommendations on human genome editingnine areas: registry, medical travel, unsafe research, IP, education
  3. 3The Hindu (AFP), "Chinese scientist fired after child death in gene-editing trial: state media" (Nov 2026)undisclosed death, exposure by *Science*/*Retraction Watch*, five-year suspension
  4. 4PIB, Parliament Question: Self reliance in CRISPR and gene editing (2026)CDSCO/NDCT Rules 2019, RCGM/IBSC oversight, BIRSA-101
  5. 5DBT, Draft Regulatory Framework and Guidelines for Genome Editing (Jan 2020)India's genome-editing framework still in draft
  6. 6WHO, *Enabling researchers to report concerns about human genome editing research* (2021)mechanisms for reporting unsafe research

More from this note